Wednesday, December 03, 2025 MA34 (BIG 4-11): A Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as AdjuvantTherapy in Patients with Operable HER2-Positive Primary Breast Cancer trial has permanently closed.The letter of permanent trial closure/termination can be found in the members' area of the CCTG webpage under "Toolbox-Reports-Trial Closure" here: https://www.ctg.queensu.ca/trials/permanent_closure/permanent-trial-closure This randomized, double-blind, placebo-controlled, two-arm study assessed the safety and efficacy of pertuzumab in addition to chemotherapy plus trastuzumab as adjuvant therapy in participants with operable HER2-positive primary breast cancer. This was a Breast International Group (BIG) study. Primary Publicationvon Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. DOI: 10.1056/NEJMoa1703643 NCT01358877: Study Results are available on www.clinicaltrials.gov
